Legend Biotech Corporation
LEGN
Pozycja w akcjach
#4424
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Cena akcji
$19.04
Kapitalizacja rynkowa
$3.52B
Zmiana (1 dzień)
2.09%
Zmiana (1 rok)
-42.15%
Kraj
US
Handel Legend Biotech Corporation (LEGN)
Kategoria
Healthcare
Wskaźnik P/B dla Legend Biotech Corporation (LEGN)
Wskaźnik P/B na dzień October 2026 TTM: 2.90
Według najnowszych raportów finansowych i ceny akcji Legend Biotech Corporation, obecny wskaźnik P/B (TTM) wynosi 2.90. Na koniec 2023 wynosił 4.23.
Historia wskaźnika P/B dla Legend Biotech Corporation od 2017 do 2026
Wskaźnik P/B na koniec każdego roku
| Rok | Wskaźnik P/B | Zmień |
|---|---|---|
| 2026 (TTM) | 2.90 | 1.24% |
| 2024 | 2.86 | -32.46% |
| 2023 | 4.23 | -20.63% |
| 2022 | 5.33 | -23.44% |
| 2021 | 6.97 | 17.36% |
| 2020 | 5.94 | -129.87% |
| 2019 | -19.88 | -109.29% |
| 2018 | 213.90 | 6.56% |
| 2017 | 200.73 | 0.00% |
Wskaźnik P/B dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/B | Różnica wskaźnika P/B | Kraj |
|---|---|---|---|
| 6.251 | 115.89% |
US
|
|
| 13.2547 | 357.77% |
US
|
|
| 4.208 | 45.33% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 113.52% |
NL
|
